Do analysts rate BGM or PLYX?

Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 275.82%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polaryx Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has better valuation and earnings, BGM or PLYX?

Polaryx Therapeutics has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.64 -$19.94M N/A N/A Polaryx Therapeutics N/A N/A -$8.98M -$0.08 N/A

Is BGM or PLYX more profitable?

Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Polaryx Therapeutics N/A N/A N/A

Do analysts prefer PYPD or BGM?

PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 117.53%. Given PolyPid's stronger consensus rating and higher possible upside, research analysts clearly believe PolyPid is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PolyPid 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, PYPD or BGM?

BGM Group has higher revenue and earnings than PolyPid. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PolyPid N/A N/A -$34.17M -$1.48 N/A BGM Group $37.92M 0.64 -$19.94M N/A N/A

Is PYPD or BGM more profitable?

BGM Group's return on equity of 0.00% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets PolyPid N/A -311.08% -150.83% BGM Group N/A N/A N/A

Does the media prefer PYPD or BGM?

In the previous week, PolyPid and PolyPid both had 1 articles in the media. PolyPid's average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BGM Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BGM or CPIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BGM or CPIX?

Cumberland Pharmaceuticals has higher revenue and earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.64 -$19.94M N/A N/A Cumberland Pharmaceuticals $44.52M 2.46 -$2.84M -$0.71 N/A

Does the media favor BGM or CPIX?

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 1 mentions for BGM Group. Cumberland Pharmaceuticals' average media sentiment score of 0.25 beat BGM Group's score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BGM Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cumberland Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CGTX or BGM?

Cognition Therapeutics currently has a consensus target price of $3.33, indicating a potential upside of 220.51%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, CGTX or BGM?

BGM Group has higher revenue and earnings than Cognition Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.17 N/A BGM Group $37.92M 0.64 -$19.94M N/A N/A

Is CGTX or BGM more profitable?

BGM Group's return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -50.17% -40.22% BGM Group N/A N/A N/A

Does the media refer more to CGTX or BGM?

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 1 articles in the media. Cognition Therapeutics' average media sentiment score of 1.34 beat BGM Group's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BGM Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, VRCA or BGM?

Verrica Pharmaceuticals has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verrica Pharmaceuticals $35.58M 2.15 -$17.89M -$1.67 N/A BGM Group $37.92M 0.64 -$19.94M N/A N/A

Does the media refer more to VRCA or BGM?

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat BGM Group's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BGM Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

BGM Group (BGM) Competitors

$0.25 -0.01 (-3.09%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.27 +0.02 (+8.76%)

As of 09/18/2026 07:09 PM Eastern

Compare

BGM vs. PLYX, PYPD, CPIX, CGTX, and VRCA

Should you buy BGM Group stock or one of its competitors? BGM Group's main competitors and comparable companies include Polaryx Therapeutics (PLYX), PolyPid (PYPD), Cumberland Pharmaceuticals (CPIX), Cognition Therapeutics (CGTX), and Verrica Pharmaceuticals (VRCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does BGM Group compare to Polaryx Therapeutics?

BGM Group (NASDAQ:BGM) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.

Polaryx Therapeutics has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.64	-$19.94M	N/A	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 275.82%. Given Polaryx Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, BGM Group had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 1 mentions for BGM Group and 0 mentions for Polaryx Therapeutics. BGM Group's average media sentiment score of 0.00 equaled Polaryx Therapeutics'average media sentiment score.

Company	Overall Sentiment
BGM Group	Neutral
Polaryx Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Polaryx Therapeutics	N/A	N/A	N/A

Summary

Polaryx Therapeutics beats BGM Group on 5 of the 7 factors compared between the two stocks.

How does BGM Group compare to PolyPid?

PolyPid (NASDAQ:PYPD) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

PolyPid currently has a consensus price target of $11.33, suggesting a potential upside of 117.53%. Given PolyPid's stronger consensus rating and higher possible upside, research analysts clearly believe PolyPid is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group has higher revenue and earnings than PolyPid.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
BGM Group	$37.92M	0.64	-$19.94M	N/A	N/A

In the previous week, PolyPid and PolyPid both had 1 articles in the media. PolyPid's average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PolyPid has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

BGM Group's return on equity of 0.00% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
BGM Group	N/A	N/A	N/A

26.5% of PolyPid shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

BGM Group beats PolyPid on 6 of the 10 factors compared between the two stocks.

How does BGM Group compare to Cumberland Pharmaceuticals?

BGM Group (NASDAQ:BGM) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Cumberland Pharmaceuticals had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for Cumberland Pharmaceuticals and 1 mentions for BGM Group. Cumberland Pharmaceuticals' average media sentiment score of 0.25 beat BGM Group's score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cumberland Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cumberland Pharmaceuticals has higher revenue and earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.64	-$19.94M	N/A	N/A
Cumberland Pharmaceuticals	$44.52M	2.46	-$2.84M	-$0.71	N/A

BGM Group has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market.

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BGM Group has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. BGM Group's return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cumberland Pharmaceuticals beats BGM Group on 6 of the 11 factors compared between the two stocks.

How does BGM Group compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Cognition Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

BGM Group has higher revenue and earnings than Cognition Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A
BGM Group	$37.92M	0.64	-$19.94M	N/A	N/A

BGM Group's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-50.17%	-40.22%
BGM Group	N/A	N/A	N/A

Cognition Therapeutics currently has a consensus target price of $3.33, indicating a potential upside of 220.51%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cognition Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 1 articles in the media. Cognition Therapeutics' average media sentiment score of 1.34 beat BGM Group's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

43.4% of Cognition Therapeutics shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BGM Group beats Cognition Therapeutics on 6 of the 11 factors compared between the two stocks.

How does BGM Group compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Verrica Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

BGM Group has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. BGM Group's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
BGM Group	N/A	N/A	N/A

Verrica Pharmaceuticals has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.15	-$17.89M	-$1.67	N/A
BGM Group	$37.92M	0.64	-$19.94M	N/A	N/A

Verrica Pharmaceuticals currently has a consensus price target of $12.67, indicating a potential upside of 184.64%. Given Verrica Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Verrica Pharmaceuticals is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Verrica Pharmaceuticals and Verrica Pharmaceuticals both had 1 articles in the media. Verrica Pharmaceuticals' average media sentiment score of 1.40 beat BGM Group's score of 0.00 indicating that Verrica Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Verrica Pharmaceuticals beats BGM Group on 7 of the 13 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGM vs. The Competition

Export

Metric	BGM Group	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.40M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	N/A	797.25	275.49	25.40
Price / Sales	0.64	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.06	10.53	10.46	6.33
Net Income	-$19.94M	$2.82B	$3.49B	$358.33M
7 Day Performance	-4.56%	1.69%	0.59%	1.12%
1 Month Performance	-4.67%	0.24%	-1.74%	-2.39%
1 Year Performance	-97.47%	3.95%	18.13%	5.35%

BGM Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGM BGM Group	0.7393 of 5 stars	$0.25 -3.1%	N/A	-97.5%	$24.40M	$37.92M	N/A	471	Gap Down
PLYX Polaryx Therapeutics	3.0051 of 5 stars	$2.05 +2.5%	$7.67 +274.0%	N/A	$102.19M	N/A	N/A	11	Gap Down
PYPD PolyPid	2.2834 of 5 stars	$5.28 -0.9%	$11.33 +114.5%	+51.0%	$100.84M	N/A	N/A	80	Positive News
CPIX Cumberland Pharmaceuticals	0.6889 of 5 stars	$6.53 -3.9%	N/A	+132.4%	$98.27M	$44.30M	N/A	80
CGTX Cognition Therapeutics	2.3167 of 5 stars	$1.03 +1.5%	$3.33 +225.2%	-25.7%	$97.47M	N/A	N/A	20	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGM) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BGM Group (BGM) Competitors

BGM vs. PLYX, PYPD, CPIX, CGTX, and VRCA

How does BGM Group compare to Polaryx Therapeutics?

Summary

How does BGM Group compare to PolyPid?

Summary

How does BGM Group compare to Cumberland Pharmaceuticals?

Summary

How does BGM Group compare to Cognition Therapeutics?

Summary

How does BGM Group compare to Verrica Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BGM Group (BGM) Competitors

BGM vs. PLYX, PYPD, CPIX, CGTX, and VRCA

How does BGM Group compare to Polaryx Therapeutics?

Which has better valuation and earnings, BGM or PLYX?

Do analysts rate BGM or PLYX?

Does the media favor BGM or PLYX?

Is BGM or PLYX more profitable?

Summary

How does BGM Group compare to PolyPid?

Do analysts prefer PYPD or BGM?

Which has higher earnings & valuation, PYPD or BGM?

Does the media prefer PYPD or BGM?

Which has more risk and volatility, PYPD or BGM?

Is PYPD or BGM more profitable?

Do institutionals & insiders have more ownership in PYPD or BGM?

Summary

How does BGM Group compare to Cumberland Pharmaceuticals?

Does the media favor BGM or CPIX?

Which has better earnings and valuation, BGM or CPIX?

Which has more risk and volatility, BGM or CPIX?

Do insiders and institutionals believe in BGM or CPIX?

Is BGM or CPIX more profitable?

Do analysts recommend BGM or CPIX?

Summary

How does BGM Group compare to Cognition Therapeutics?

Which has more volatility and risk, CGTX or BGM?

Which has higher valuation & earnings, CGTX or BGM?

Is CGTX or BGM more profitable?

Do analysts rate CGTX or BGM?

Does the media refer more to CGTX or BGM?

Do insiders and institutionals believe in CGTX or BGM?

Summary

How does BGM Group compare to Verrica Pharmaceuticals?

Which has more volatility and risk, VRCA or BGM?

Is VRCA or BGM more profitable?

Which has preferable valuation & earnings, VRCA or BGM?

Do analysts rate VRCA or BGM?

Does the media refer more to VRCA or BGM?

Do institutionals and insiders believe in VRCA or BGM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools